Journal of Infectious Diseases & Preventive Medicine
Open Access
ISSN: 2329-8731
+44 1300 500008
ISSN: 2329-8731
+44 1300 500008
Department of Pharmaceuticals, University of Abbott Healthcare, Mumbai, Maharashtra, India
Research
Use of a Kappa-carrageenan Nasal Solution in the Prophylaxis Treatment of Respiratory Infection Against Viruses Influenza (H1N1), Coronavirus (SARS-CoV-2) and Chronic Obstructive Pulmonary Diseases (COPD)
Author(s): Padmanabha Reddy RV*
Purpose: The nasal mucosa is the primary site of infection and replication for most cold-causing viruses including influenza (H1N1) and SARS-CoV-2. It was hypothesized, carrageenan’s would block viral entry at respiratory mucosa and interfere with viral replication propagation locally. The goal of this experiment was to test the antiviral effects of kappa carrageenan and Iota carrageenan in fully differentiated human airway epithelial cells cultivated at the airliquid interface against influenza (H1N1) and SARS-CoV-2 virus infection.
Methods: To assess the efficacy of test product on human airway epithelial cells, apical viral replication (genome copy number) was quantified, tissue integrity was measured. Epithelia (MucilAir™-Pool) cells were used for the study. The experiment was designed to test the antiviral effects of kappa c.. View More»
DOI:
10.35841/2329-8731.23.12.338